Delpacibart Etedesiran Shows Promise in Addressing the Molecular Root of Myotonic Dystrophy Type 1

The Clinical Challenge of Myotonic Dystrophy Type 1

Myotonic dystrophy type 1 (DM1) represents a significant burden in the landscape of neuromuscular medicine. As a rare, dominantly inherited, and progressive multisystemic disorder, it is characterized by myotonia, progressive muscle wasting, cardiac conduction defects, and cognitive impairment. For clinicians and patients alike, the lack of approved disease-modifying therapies has long been a source of frustration, leaving management focused solely on symptomatic relief and supportive care. The disease is caused by a trinucleotide (CTG) repeat expansion in the 3′ untranslated region of the DMPK gene, which encodes the myotonic dystrophy protein kinase. This expansion imparts a toxic gain of function to the transcribed messenger RNA (mRNA), which forms stable hairpin loops that sequester essential splicing factors, such as the Muscleblind-like (MBNL) protein family. This sequestration leads to widespread dysregulation of alternative splicing—termed missplicing—across hundreds of transcripts, ultimately driving the diverse clinical manifestations of the disease.

Mechanism of Action: The Antibody-Oligonucleotide Conjugate (AOC) Approach